My groups’ primary research interests are in the genomics and molecular pathology of pancreatic cancer and the development of oncolytic virotherapy.
We work on cancer prevention and immunotherapy using tumour-targeted replicating oncolytic viruses, in particular focusing on replicating adenovirus and vaccinia virus.
Our research focuses on the use of modified, replicating oncolytic Vaccinia viruses and adenoviruses armed with immune-modulatory genes such as cytokines to create a self-propagating treatment for tumours that results in long-term immunological memory to the tumour cells.
My project is focused on the identification of molecular factors affecting adenoviral therapy.
My research focuses on Vaccinia virus (VACV) as a candidate for oncolytic virotherapy, an extremely effective strategy that can simultaneously target multiple features of the suppressive tumour microenvironment (TME) in cancer and sensitize the tumours to other forms of immune or traditional therapeutics.
My research is focused on cancer immunotherapy for pancreatic cancer, particularly immune-stimulatory molecules, armed oncolytic viruses and CAR T-cells.